PDF(Pubmed)
Abstract：
Sjögren syndrome (SS) is a long-lasting inflammatory autoimmune disease that may cause diverse manifestations, particularly osteoporosis. Though usage of Chinese herbal medicine (CHM) can safely manage autoimmune disease and treatment-related symptoms, the relation between CHM use and osteoporosis risk in SS persons is not yet recognized. With that in mind, this population-level nested case-control study aimed to compare the risk of osteoporosis with and without CHM use. Potential subjects aged 20-70 years, diagnosed with SS between 2001 and 2010, were retrieved from a national health claims database. Those diagnosed with osteoporosis after SS were identified and randomly matched to those without osteoporosis. We capitalize on the conditional logistic regression to estimate osteoporosis risk following CHM use. A total of 1240 osteoporosis cases were detected and randomly matched to 1240 controls at a ratio of 1:1. Those receiving conventional care plus CHM had a substantially lower chance of osteoporosis than those without CHM. Prolonged use of CHM, especially for one year or more, markedly dwindled sequent osteoporosis risk by 71%. Integrating CHM into standard care may favor the improvement of bone function, but further well-designed randomized controlled trials to investigate the possible mechanism are needed.
摘要：
干燥综合征（SS）是一种持久的炎症性自身免疫性疾病，可引起多种表现，特别是骨质疏松症。虽然使用中草药（CHM）可以安全地管理自身免疫性疾病和治疗相关症状，SS患者使用CHM与骨质疏松风险之间的关系尚不明确.考虑到这一点，这项人群水平的巢式病例对照研究旨在比较使用和不使用CHM的骨质疏松症风险.年龄在20-70岁的潜在受试者，2001年至2010年间诊断为SS，从国家健康索赔数据库中检索。确定SS后诊断为骨质疏松症的患者，并与无骨质疏松症的患者随机匹配。我们利用条件逻辑回归来估计使用CHM后骨质疏松症的风险。共检测到1240例骨质疏松症病例，并以1：1的比例与1240例对照进行随机匹配。那些接受常规护理加CHM的人比没有CHM的人患骨质疏松症的几率大大降低。长期使用CHM，尤其是一年或一年以上，随之而来的骨质疏松症风险显著减少了71%。将CHM纳入标准护理可能有利于骨功能的改善，但需要进一步精心设计的随机对照试验来研究可能的机制.
